Clostridium perfringens type B (C. perfringens type B)

Clostridium perfringens type B is a Gram-positive, anaerobic, spore-forming bacterium that serves as a significant pathogen in veterinary medicine, primarily affecting ruminants like lambs, calves, and foals [1, 2]. It is distinguished from other C. perfringens types by its ability to produce three major lethal toxins: Alpha toxin (CPA), Beta toxin (CPB), and Epsilon toxin (ETX) [3, 5]. The pathogenesis of Type B infection, often manifesting as lamb dysentery or hemorrhagic enteritis, is driven by the synergistic action of these toxins, which cause severe intestinal damage and systemic toxemia [2, 3]. Beta toxin acts as a pore-forming agent targeting endothelial cells via the CD31 receptor, while Epsilon toxin increases vascular permeability and can cross the blood-brain barrier by binding to the MAL protein [4, 5]. Therapeutic strategies focus on the use of antibiotics like penicillin to eliminate the bacteria and the administration of toxoid vaccines or antitoxins to neutralize the lethal effects of the secreted toxins [2, 3]. Although primarily a veterinary concern, the molecular study of its toxins provides insights into bacterial pathogenesis and the development of host-directed therapies [1, 4].

Other names

Lamb dysentery bacillusClostridium welchii type BC. perfringens biotype B

Inhibition of bacterial cell wall synthesis and neutralization of secreted pore-forming and enzymatic toxins